Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP

Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP Within a Protocol of Controlled Ovarian Hyperstimulation in IVF in Normoresponders Women Undergoing Downregulation With GnRH Antagonist

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01330771

Enrollment

Registered

2011-04-07

Start date

2006-10-31

Completion date

2008-09-30

Last updated

2011-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sterility

Brief summary

To assess the effectiveness of a protocol of ovarian hyperstimulation combining urinary gonadotrophins + recombinant gonadotrophins, to achieve clinical pregnancy in females undergoing IVF. Study hypothesis: to assess the effectiveness of protocols combining urinary gonadotrophins + recombinant gonadotrophins

Interventions

DRUGhMG-HP/r-FSH

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Inclusion criteria

* Women aged 18-38 years * Body mass index (BMI) between 18 and 30 * Women classified as normogonadotrophin patients. Not more than 3 previous cycles of ART (assisted reproductive technology) * Testosterona, FSH (follicle-stimulating hormone), LH (luteinizing hormone) and Prolactin serum levels during the early folicular phase (days 2-4 of the cycle) within the laboratory normal range * No administration of clomiphen citrate or gonadotropins during the month prior to the start of the study

Exclusion criteria

* Failure in previous cycles of assisted reproduction IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) * Seminal samples not apt for IVF-ICSI (according to the criteria of each center). Evidence of significant bacterial infection in the seminogram of the couple in the preceding 6 months * Data suggestive of possible ovarian failure * Antecedents of severe ovarian hyperstimulation syndrome (OHSS) * Important systemic disease * Pregnancy or contraindication to pregnancy

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate	30 days

Secondary

Measure	Time frame
Biochemical pregnancy rate	16 days

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026